Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 2102-2110

  Kobayashi, Yoshimasa ^a   Sridar, Chitra ^a   Kent, Ute M ^a   Puppali, Satish G ^b   Rimoldi, John M ^b   Zhang, Haoming ^c   Waskell, Lucy ^c   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 METHOXYPHENYL) 3 (TRIFLUOROMETHYL)DIAZIRIDINE; 3 (4 CHLOROPHENYL) 3 (TRIFLUOROMETHYL)DIAZIRIDINE; 3 (TRIFLUOROMETHYL)3 PHENYLDIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (3 METHOXYPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (3 METHYL4 METHOXYPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (3,4 DIMETHOXYPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (3,4,5 TRIMETHOXYPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (4 CHLOROPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (4 METHOXYPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 (4 METHOXYPHENYL)ETHANONE; 3 TRIFLUOROMETHYL 3 (4 METHYLTHIOPHENYL)DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 [4 (METHYLTHIO)PHENYL]DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 PHENYL DIAZIRIDINE; 3 TRIFLUOROMETHYL 3 PHENYLDIAZIRIDINE; 3,4 ETHOXYPHENYL 3 (TRIFLUOROMETHYL)DIAZIRIDINE; 4 ETHYLIDENE CYCLOHEXA 2,5 DIENONE; 7 ETHOXY 4 (TRIFLUOROETHYL)COUMARIN; AZIRIDINE DERIVATIVE; CYTOCHROME P450 2B6; DRUG METABOLITE; GLUTATHIONE ETHYL ESTER; PHENYLDIAZIRIDINE DERIVATIVE; QUINONE DERIVATIVE;

ARTICLE; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INACTIVATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY;

ARYL HYDROCARBON HYDROXYLASES; AZIRIDINES; COUMARINS; GLUTATHIONE; OXIDOREDUCTASES, N-DEMETHYLATING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33751531910     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011452     Document Type: Article

References (29)

1. Brunner J, Senn H, and Richards FM (1980) 3-Trifluoromethyl-3- phenyldiazirine. J Biol Chem 255:3313-3318.
2. Cho H, Beale JM, Graff C, Mocek U, Nakagawa A, Omura S, and Floss HG (1993) Studies on the biosynthesis of the antibiotic reductiomycin in Streptomyces xanthochromogenus. J Am Chem Soc 115:12296-12304.
3. Correia MA and Ortiz de Montellano PR (2005) Inhibition of cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed (Ortiz de Montellano PR ed) pp 247-322. Kluwer Academic/Plenum Publishers, New York.
4. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16.
5. Fan PW and Bolton JL (2001) Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab Dispos 29:891-896.
6. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, and Mansuy D (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112-12122.
7. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216.
8. Hanna IH, Teiber JF, Kokones KL, and Hollenberg PF (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys 350:324-332.
9. Hatanaka Y, Hashimoto M, Kurihara H, Nakayama H, and Kanaoka Y (1994) A novel family of aromatic diaziridines for photoaffinity labelling. J Org Chem 59:383-387.
10. Hatanaka Y, Nakayama H, Kanaoka Y (1996) Diazirine-based photoaffinity labeling: chemical approach to biological interfaces. Rev Heteroat Chem 14:213-243.
11. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, and Woolf TF (2004) Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos 32:639-646.
12. Jones DR and Hall SD (2002) Mechanism-based inhibition of human cytochromes P450: in vitro kinetics and in vivo correlations, in Drug and Pharmaceutical Sciences vol 116: Drug-Drug Interactions (Rodrigues AD Ed) pp 387-413. Marcel Dekker, Inc., New York.
13. Kesavan V, Bonnet-Delpon D, Begue J-P, Srikanth A, and Chandrasekaran S (2000) New catalytic oxidation of trifluoromethyl carbinols by a ruthenium(II) complex. Tetrahedron Lett 41:3327-3330.
14. Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, and Trager WF (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 38:2312-2319.
15. Lim HK, Duczak N Jr, Brougham L, Elliot M, Patel K, and Chan K (2005) Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211-1219.
16. Lopez-Garcia MP, Dansette PM, and Mansuy D (1994) Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33:166-175.
17. Lopez Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, Guengerich FP, and Mansuy D (1993) Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur J Biochem 213:223-232.
18. Monks TJ and Jones DC (2002) The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr Drug Metab 3:425-438.
19. Nassar AE and Lopez-Anaya A (2004) Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discov Dev 7:126-136.
20. Reddy VB, Karanam BV, Gruber WL, Wallace MA, Vincent SH, Franklin RB, and Baillie TA (2005) Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. Chem Res Toxicol 18:880-888.
21. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
22. Seguin B and Uetrecht J (2003) The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 3:235-242.
23. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, and Contillo LG (2004) The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro- electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal 36:105-116.
24. Sridar C, Kobayashi Y, Brevig H, Kent UM, Puppali SG, Rimoldi JM, and Hollenberg PF (2006) Synthesis of substituted phenyl diaziridines and characterization as mechanism-based inactivators of human cytochrome P450 2B6. Drug Metab Dispos 34:1849-1855.
25. Uetrecht J (2003a) Bioactivation, in Drug Metabolism Enzymes: Cytochrome P450 and P450 and Other Enzymes in Drug Discovery and Development (Lee JS, Obach RS, and Fisher MB eds) Fontis Media S.A., Lausanne/Marcel Dekker Inc., New York, pp87-145.
26. Uetrecht J (2003b) Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 8:832-837.
27. Yamamoto Y, Yamazaki H, Ikeda T, Watanabe T, Iwabuchi H, Nakajima M, and Yokoi T (2002) Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos 30:155-160.
28. Yan D, Zhang F, Yu L, Yang Y, van Breemen RB, and Bolton JL (2001) Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: Droloxifene and toremifene o-quinones. Chem Res Toxicol 14:1643-1653.
29. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, and McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.